Treatment
SHR-A1811 clinical trials
We’re tracking 38 recruiting studies that include SHR-A1811, each written for real people, not researchers, below.
Recruiting studies
- NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05635487RecruitingPhase 2
Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Shenyang, LiaoningAges 18–75 - NCT07817082RecruitingPhase 2
A new drug for her2 ultra-low advanced breast cancer
This study tests a new targeted drug (SHR-A1811) for breast cancer that has very low HER2 levels. The drug is designed to attack cancer cells with this specific marker, and the study aims to see if it can help slow the cancer's growth.
TianjinAges 18–75 - NCT06015048RecruitingPhase 1/Phase 2
SHR-A1811 plus other therapies for advanced HER2+ tumors
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
Hefei, AnhuiAges 18–75 - NCT07676162RecruitingPhase 3
New targeted drug combo for advanced colorectal cancer
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT05911958RecruitingPhase 2
Study drug before surgery for HER2-low, HR-positive breast cancer
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
Zhengzhou, HenanAges 18–70 - NCT06222879RecruitingPhase 1/Phase 2
New drug combinations for advanced breast cancer
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Changsha, HunanAges 18–75 - NCT06340230RecruitingPhase 2
New drug combination before surgery for HR+ HER2-low breast cancer
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
Shenyang, LiaoningAges 18–75 - NCT06718933RecruitingPhase 1/Phase 2
Study of a drug combination for breast cancer that spread to the brain
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06778031RecruitingPhase 2
Study of SHR-A1811 for HER2-positive bile duct cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
Harbin, HeilongjiangAges 18–75 - NCT07275242RecruitingPhase 1
Study of SHR-A1811 injection for solid tumors
This study tests an experimental drug called SHR-A1811 given as a shot under the skin (subcutaneous injection) for people with solid tumors. It aims to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18 years+ - NCT07231211RecruitingPhase 1/Phase 2
Testing SHR-4610 for advanced solid tumors
This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.
Hangzhou, ZhejiangAges 18–75 - NCT07118527RecruitingPhase 3
New drug combo for untreated advanced stomach cancer
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Shenyang, LiaoningAges 18–75 - NCT07111832RecruitingPhase 3
Study of SHR-A1811 for triple-negative breast cancer
This study tests a new drug called SHR-A1811 for people with triple-negative breast cancer that has spread or come back. It looks at whether the drug can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07110571RecruitingPhase 2
Combination therapy study for untreated stomach or GEJ cancer
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
Shijiazhuang, HebeiAges 18–70 - NCT07102901RecruitingPhase 2
Study of SHR2554 with other therapies for gastric or junction cancer
This trial tests a new drug, SHR2554, combined with other anticancer treatments for advanced stomach or gastroesophageal junction cancer. It aims to see if the combination is safe and effective. You may qualify if you have measurable disease and are generally in good health.
Harbin, HeilongjiangAges 18–75 - NCT07051486RecruitingPhase 2
SHR-A1811 for HER2-positive recurrent or metastatic cervical cancer
This trial tests a new drug, SHR-A1811, that targets a protein called HER2 found on some cervical cancer cells. It's for women whose cervical cancer has returned or spread and is not responding to other treatments.
Fuzhou, FujianAges 18–75 - NCT06859775RecruitingPhase 1/Phase 2
SHR-A1811 combination for recurrent or metastatic cervical cancer
This study tests whether a new drug combination called SHR-A1811 can help people with cervical cancer that has come back or spread. It aims to find a better treatment option for those who have limited choices.
Beijing, Beijing MunicipalityAges 18–75 - NCT06927180RecruitingPhase 2
Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Zhengzhou, HenanAges 18–70 - NCT06840002RecruitingPhase 1/Phase 2
Targeted drug plus chemotherapy for recurrent ovarian cancer
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06828354RecruitingPhase 3
Study of SHR-A1811 for ovarian cancer
This trial tests a new drug called SHR-A1811 for ovarian cancer. It may help people whose cancer can be measured on scans and who are still well enough to do daily activities.
Wuhan, HubeiAges 18–75 - NCT06649331RecruitingPhase 2
Re-trying antibody-drug conjugates for advanced breast cancer
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06547736RecruitingPhase 2
Precision treatment for advanced pancreatic cancer
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06433609RecruitingPhase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75
What SHR-A1811 is being studied for
Conditions with recruiting SHR-A1811 studies.
Common questions
- Are there clinical trials studying SHR-A1811?
- Yes. Clin2 currently lists 38 recruiting studies that include SHR-A1811, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a SHR-A1811 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is SHR-A1811 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether SHR-A1811 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.